Allied Gold Breaks. IMXI Climbs to #1 in Risk/Reward. #ArbLens250 — Thank You!

Allied Gold’s own chairman had told the Globe and Mail termination was “on the table.” On July 29, it happened: Zijin and Allied Gold mutually agreed there was no reasonable likelihood NDRC clearance would arrive even with more time, and walked from the C$44.00, C$5.5B all-cash deal. In its place, same day: Zijin subscribed for ~12.8M new Allied Gold shares at C$32.55 (the 30-day VWAP) for ~US$295M, taking a ~9.2% stake, expected to close around August 10. Proceeds fund the Kurmuk ramp-up, Sadiola expansion, and CDI Complex growth.

This is the precedent we flagged weeks ago playing out almost exactly: Hanlong (2012), where China's NDRC deemed Hanlong Group's bid for Sundance Resources' African iron-ore assets too expensive and demanded a "reasonable price," forcing a ~21% cut — and the repriced deal collapsed anyway months later. Here, NDRC forced nothing explicit and there was no formal haircut demand; the parties simply ran out of patience with the review timeline. But the outcome rhymes closely: a forced discount didn't save Hanlong's deal, and here the discount (a ~26% smaller stake at a fraction of the price) came without even attempting to save the original deal at all. We laid out a second, more recent comparison in “History Doesn’t Repeat, But It Rhymes: AAUC vs. NXPI” — Qualcomm's 2018 break with NXP on the same NDRC dynamic, where the target fell hard, drifted lower for months on arb deleveraging and tax-loss selling, then went on to trade multiples higher within two years. AAUC is now archived in the Broken Deals tab, with a direct link through to the full ArbLens Analysis for anyone reviewing the timeline.

IMXI widened from ~23% to 35% this week, and the honest read is sympathy, not sabotage. Western Union’s Q2 print on July 30 cut FY26 adjusted EPS guidance ~28% on Americas retail softness and the delayed synergies from this very deal — shares fell double digits same-day. IMXI dropped alongside it. The same release, though, explicitly reaffirmed a September 1 close and management said it remains “optimistic” on the last approval: NYDFS, with 51 of 52 US jurisdictions already done.

The sharper risk isn’t mechanical — it’s appetite. A financially stressed acquirer has more incentive to treat any NYDFS-imposed condition as a cheap walk-away, layered on IMXI’s own standalone EBITDA deterioration since signing. On precedent: NYDFS has blocked deals before (Ocwen 2014, Fidelity-Stewart 2019 at ~50% market concentration), but this corridor sits at only ~26% share — a real risk, not a close analog. We went deeper on the NYDFS precedents and why New York differs from the other 51 approving jurisdictions in our earlier IMXI deep dive. Net: promoted to #1 in the Risk/Reward ranking this week.

The $24.80 all-cash tender expired July 24 at ~31.6% of the non-Diana float, short of a majority. On July 27, Diana went further and terminated the offer outright — framing the withdrawal as removing Genco’s stated excuse for refusing to negotiate. The separate, non-binding $27.34 indicative proposal remains on the table; Genco’s board says it’s still reviewing it and points to its own Q2 earnings (Aug 5) as the next update. There is currently no tender mechanism at all for shareholders to act on — this is a bilateral standoff with no forced timeline, and it stays out of the Risk/Reward ranking for exactly that reason.

Per the July 24 stipulation, Paramount and the state AGs/WGA had to file competing trial-schedule proposals by July 31 — and they landed far apart, with no agreement. Paramount wants a 12-day trial starting November 4, 2026, arguing it resolves uncertainty fastest and limits the ~$7M/day ($650M/quarter) ticking fee that starts accruing after September 30. The 12 state AGs led by California's Bonta, joined by the WGA, want a 12-15 day trial starting April 5, 2027, citing the need for fuller expert discovery.

Judge Araceli Martinez-Olguin hasn't ruled yet, and this is a real swing factor, not a formality: a November trial could produce a merits result months before the outside date; an April trial pushes resolution close to the March 2027 deadline (extendable to June 1) and meaningfully raises Paramount's cumulative ticking-fee bill. Until she rules, both dates are live scenarios — and the spread compensates for that uncertainty either way.

The Hapag-Lloyd overhang everyone's watching hasn't moved: $35 cash, Israeli government opposition still unresolved, 11 regulatory authorities still to clear. The one most aren't watching: the freight cycle turned. Transpacific spot rates roughly doubled off May lows into early July, and Maersk raised FY26 EBITDA guidance sharply on the same dynamic (to $8-10B from $4.5-7B). ZIM runs ~65-70% spot exposure on its biggest trade — nobody's more levered to this move, in either direction.

Worth a caveat: rates had already begun softening again by late July as the tariff-truce front-loading effect faded, so this may be a sharp temporary spike rather than a confirmed structural upcycle. ZIM skipped its Q1 call given the pending deal, so August 19 is the real tell — the first quarter that shows how much of this actually flows through. The kicker if it does: ZIM's dividend policy pays out 30% of quarterly net income, up to 50% annually, and the company has returned $48+/share since IPO, including $17/share in a single quarter back in 2022. If the deal breaks, standalone ZIM likely looks better than the ~$25 tape implies today. If it closes, $35. Either way, the setup just improved.

Barnes didn't lean into the buyback. He went hunting: a $100M cash acquisition of Universal Shield Insurance Group (specialty P&C, licensed in 49 states), closing Q1 2027 — redeploying Fortegra proceeds straight back into insurance. The buyback itself was modest: just $10.3M of the $20M authorization used in H1, at an average $16.80.

Book value now sits at $907M, or $24.34/share — even higher than our earlier $23.80 estimate. The stock trades around $18.45, still ~24% below book. The discount has narrowed a lot since our first ArbLens special situations post flagged it at 40% — but it hasn't closed.

All regulatory approvals are in, and the $210/share, ~$55B take-private by PIF/Silver Lake/Affinity closes on or about August 4 — the largest LBO in history. The overlooked angle: EA is an S&P 500 constituent, and taking it private forces an index replacement. Precedent is exact and recent — when Devon’s acquisition of Coterra closed, Veeva got the index nod on April 30 and gapped up ~10% same day on pure passive-fund buying, no fundamentals attached.

S&P hasn’t named EA’s replacement yet. Screening every name that clears the bar — size, liquidity, sustained profitability — the ones that keep surfacing: $BE (Bloom Energy, the AI-power-demand story, now clears every threshold), plus $RDDT, $SOFI, $AFRM, $ALNY. Whoever gets picked, index funds have to buy on day one. That seat is worth watching as closely as the buyout itself.

Avanos completed its $25.00/share sale to American Industrial Partners on July 27. Open Lending’s tender to ANV succeeded at 85.65% participation, with the follow-on merger completing July 30. Both fully archived with spread history intact.